Molecular design for recombinant adeno-associated virus (rAAV) vector production.

Molecular design for recombinant adeno-associated virus (rAAV) vector production.
复制标题

重组腺相关病毒(RAAV)载体产生的分子设计。

DOI:
10.1007/s00253-017-8670-1
复制
发表时间:
2018-03
影响因子:
5
通讯作者:
Gold D
Gold D
中科院分区:
工程技术2区
文献类型:
--
作者:
Aponte-Ubillus JJ;Barajas D;Peltier J;Bardliving C;Shamlou P;Gold D

文献摘要

参考文献

被引文献

相似文献

重组腺相关病毒(rAAV)载体是基因治疗应用中越来越受欢迎的工具。它们的非致病性状态、低炎症潜力、具有不同组织嗜性的病毒血清型的可用性以及前瞻性的持久基因表达是rAAVs安全有效治疗选择的重要属性。在过去的三十年里,几个研究小组已经设计了重组AAV生产平台,产生了高滴度的转导载体颗粒。目前,不同平台的比生产率范围为每个细胞103至105个载体基因组(vg),并且正在努力提高载体产量,以满足临床试验和未来商业化所需的高产品需求。载体生产的关键方面包括产生rAV的宿主细胞系的分子设计沿着AV基因、启动子和调节元件的设计。适当地配置和平衡这些元素的表达不仅有助于提高生产率,还可以提高过程鲁棒性和产品质量。在这个小审查,rAAV生产表达系统的合理设计进行了讨论,特别注意分子策略,有助于高产,生物制造适合rAAV生产过程。详细介绍了从四个rAAV表达系统的分子优化:腺病毒,疱疹病毒,杆状病毒互补系统,以及最近探索的酵母表达系统。
Recombinant adeno-associated virus (rAAV) vectors are increasingly popular tools for gene therapy applications. Their non-pathogenic status, low inflammatory potential, availability of viral serotypes with different tissue tropisms, and prospective long-lasting gene expression are important attributes that make rAAVs safe and efficient therapeutic options. Over the last three decades, several groups have engineered recombinant AAV-producing platforms, yielding high titers of transducing vector particles. Current specific productivity yields from different platforms range from 103 to 105 vector genomes (vg) per cell, and there is an ongoing effort to improve vector yields in order to satisfy high product demands required for clinical trials and future commercialization. Crucial aspects of vector production include the molecular design of the rAAV-producing host cell line along with the design of AAV genes, promoters, and regulatory elements. Appropriately, configuring and balancing the expression of these elements not only contributes toward high productivity, it also improves process robustness and product quality. In this mini-review, the rational design of rAAV-producing expression systems is discussed, with special attention to molecular strategies that contribute to high-yielding, biomanufacturing-amenable rAAV production processes. Details on molecular optimization from four rAAV expression systems are covered: adenovirus, herpesvirus, and baculovirus complementation systems, as well as a recently explored yeast expression system.
DOI: 10.1073/pnas.0810614106
发表时间: 2009-03-31
影响因子: 11.1
作者:
Aslanidi, George;Lamb, Kenneth;Zolotukhin, Sergei
通讯作者: Zolotukhin, Sergei
DOI: 10.1006/mthe.2001.0591
发表时间: 2002-05-01
期刊: MOLECULAR THERAPY
影响因子: 12.4
作者:
Gao, GP;Lu, FM;Wilson, JM
通讯作者: Wilson, JM
DOI: 10.1186/1475-2859-11-124
发表时间: 2012-09-11
影响因子: 6.4
作者:
Backovic A;Cervelli T;Salvetti A;Zentilin L;Giacca M;Galli A
通讯作者: Galli A
DOI: 10.1038/sj.gt.3300937
发表时间: 1999-06-01
期刊: GENE THERAPY
影响因子: 5.1
作者:
Conway, JE;ap Rhys, CMJ;Byrne, BJ
通讯作者: Byrne, BJ
DOI: 10.1128/jvi.71.9.6816-6822.1997
发表时间: 1997-09-01
影响因子: 5.4
作者:
Allen, JM;Debelak, DJ;Miller, AD
通讯作者: Miller, AD